Manufacturer
GLAXOSMITHKLINE BIOLOGICALS S.A
Contents
Live attenuated Oka strain of varicella-zoster virus not <103.3 plaque-forming units (PFU)
Indication
Active immunisation against varicella of healthy subjects ≥12 mth, susceptible high-risk patients & their susceptible healthy close contacts.
Instruction
SC Adult, adolescent ≥13 yr & childn 12 mth-12 yr 2 doses w/ 2nd dose given at least 6 wk after 1st dose & not <4 wk.
Drug interaction
Temporary depression of tuberculin skin sensitivity. Delay vaccination at least 3 mth in patients who have received immune globulins or blood transfusion. Reye's syndrome w/ salicylates. Short lived suppression of cell mediated immune response w/ measles vaccine. Not to be administered at the same time w/ other live attenuated vaccines.
Malaysia
